磷酸化失调症蛋白1抗体Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord.磷酸化失调症蛋白1抗体 Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, 磷酸化失调症蛋白1抗体producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains41-81 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1).
磷酸化失调症蛋白1抗体Also known as:
Ataxin-1 (phospho-Ser238); Ataxin-1 (phospho S238); ATXN1; ATX1; D6S504E; SCA1; Ataxin-1; Spinocerebellar ataxia type 1; ATX1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Dog, Horse, Rabbit, Guinea Pig, .
●
Immunogen: KLH conjugated synthesised phosphopeptide derived from human ATXN1 around the phosphorylation site of Ser238.
●
磷酸化失调症蛋白1抗体Predicted Molecular Weight: 90kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
l215Hu01Ⅰ型胶原α2(COL1α2)多克隆抗体Polyclonal Antibody to Collagen Type I Alpha 2 (COL1a2)
kl215Rb51Ⅰ型胶原α2(COL1α2)多克隆抗体Polyclonal Antibody to Collagen Type I Alpha 2 (COL1a2)
kl216Ca01单核细胞趋化蛋白4(MCP4)多克隆抗体Polyclonal Antibody to Monocyte Chemotactic Protein 4 (MCP4)
kl216Eq01单核细胞趋化蛋白4(MCP4)多克隆抗体Polyclonal Antibody to Monocyte Chemotactic Protein 4 (MCP4)
kl216Hu01单核细胞趋化蛋白4(MCP4)多克隆抗体Polyclonal Antibody to Monocyte Chemotactic Protein 4 (MCP4)
kl217Bo01α1-微球蛋白(α1M)多克隆抗体Polyclonal Antibody to Alpha-1-Microglobulin/Bikunin Precursor (a1M)
kl217Gu01α1-微球蛋白(α1M)多克隆抗体Polyclonal Antibody to Alpha-1-Microglobulin/Bikunin Precursor (a1M)
kl217Po01α1-微球蛋白(α1M)多克隆抗体Polyclonal Antibody to Alpha-1-Microglobulin/Bikunin Precursor (a1M)
kl218Bo01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Ca01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Cp01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Ga01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Po01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Rb51转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl218Si01转化生长因子β2(TGFβ2)多克隆抗体Polyclonal Antibody to Transforming Growth Factor Beta 2 (TGFb2)
kl220Bo01肾上腺髓质素(ADM)多克隆抗体Polyclonal Antibody to Adrenomedullin (ADM)
kl220Ca01肾上腺髓质素(ADM)多克隆抗体Polyclonal Antibody to Adrenomedullin (ADM)
更多
企业名称
上海康朗生物科技有限公司
企业信息已认证
企业类型
信用代码
310112001510759
成立日期
2015-05-29
注册资本
100
经营范围
从事生物科技技术领域内技术开发、技术咨询、技术服务、技术转让,实验分析仪器、化工产品及原料(除危险化学品、监控化学品、烟花爆竹、民用爆竹物品、易制毒化学品)、仪器仪表、环保设备、酒店用品、皮革制品、床上用品、电子产品的销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上海康朗生物科技有限公司
公司地址
上海市闵行区闵北路88弄1-30号第22栋BV145室
客服电话